Toronto Skyline for WCLC
There’s a lot going on in lung cancer of late, especially with the World Conference on Lung Cancer (WCLC) taking place in Toronto this week.
Following on from our recent preview, it’s time to take a look at the actual data presented and make an assessment on progress with both targeted and immunotherapies.
Here we offer some thoughts and insights on 16 key trials that were presented…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Picking out gems from the weeds
It’s time for a pre-meeting preview as we head into the busy Fall cancer conference season.
First up is the IASLC organised World Conference on Lung Cancer (WCLC) being held in Toronto later this month.
We provide a review of some of the key abstracts and highlight some of the interesting topics to watch out for.
Updates will follow later once the data is presented as many of the abstracts are embargoed until the day of presentation.
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Following yesterday’s review of a dozen key oral abstract sessions to watch out for at ASCO18 next month including lung cancer and others, we now take a look at the other side of the coin with a dozen key poster abstracts to explore.
- Which topics jump out this year?
- What new targets and molecules are the emergent gems to think about?
- What can we learn from translational and early combination clinical data?
Take a walk with us on our journey to Chicago ahead of the data drop at 5pm…
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the last count, the renal cell carcinoma (RCC) space is quite competitive with five VEGF inhibitors (sunitinib, sorafenib, axitinib, pazopanib and bevacizumab), two mTOR blockers (temsirolimus and everolimus) and not forgetting IL–2, all approved by the FDA for the treatment of advanced disease.
Much of the recent focus has been on sequencing, exploring combinations (generally too toxic with little added benefit), and evaluating the potential for novel immunotherapies in development such as checkpoint inhibitors. Biomarkers are few and far between, making it hard to rationally decide which therapy each patient should get and in which sequence.
The key question is, why is this tumour type so challenging from a clinical and scientific perspective?
Recently, new data has begun to emerge that may help inform or enable us to switch to new approaches. While the urologists are eagerly watching the live surgery on the EAU cam, we highlight research data presented at the European Association of Urology (EAU) in Madrid and take a look at how the underlying biology of RCC can elevate our knowledge about where the potential future strategies and blueprint might lie, if we want to facilitate exciting new developments in this field.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.